Skip to main content
. 2015 Apr 23;2015:457613. doi: 10.1155/2015/457613

Figure 2.

Figure 2

Kaplan-Meier survival analysis of the patient cohort: median overall survival was significantly longer in the responder group compared with nonresponders to terlipressin therapy: 29 months [95% CI 20.7–38.4] versus 8 months [95% CI 0.0–16.3] (treatment responders versus nonresponder group, log-rank test, p = 0.007).